1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 7, 20/Feb/2025
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We estimated early influenza vaccine effectiveness (VE) for the 2024/25 season in outpatients, in Beijing using a test-negative design. A(H1N1)pdm09 dominated (99.3%), all sequenced strains (n = 38) clustered in clade 6B.1A.5a.2a, and 37 of 38 antigenically similar to the vaccine strain. VE against any influenza virus infection was 48.5% (95% CI: 34.8–59.5) and 48.7% (95% CI: 35.1–59.7) against A(H1N1)pdm09. Vaccination in the current or previous season against any influenza showed a VE of 52.5% to 54.9%, compared to no vaccination in both seasons.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.7.2500084
2025-02-20
2025-02-26
/content/10.2807/1560-7917.ES.2025.30.7.2500084
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/7/eurosurv-30-7-4.html?itemId=/content/10.2807/1560-7917.ES.2025.30.7.2500084&mimeType=html&fmt=ahah

References

  1. Zhang Y, Muscatello DJ, Wang Q, Yang P, Wu J, MacIntyre CR. Overview of influenza vaccination policy in Beijing, China: Current status and future prospects. J Public Health Policy. 2017;38(3):366-79.  https://doi.org/10.1057/s41271-017-0079-7  PMID: 28512300 
  2. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination recommendations and coverage rates in EU/EEA Member States–An overview of vaccination recommendations for 2021−22 and coverage rates for the 2018−19 to 2020−21 influenza seasons. Stockholm: ECDC. [Accessed: 10 Jan 2025]. Available from: https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-recommendations-and-coverage-rates-eueea-member
  3. Palache A, Oriol-Mathieu V, Abelin A, Music T, Influenza Vaccine Supply task force (IFPMA IVS). Seasonal influenza vaccine dose distribution in 157 countries (2004-2011). Vaccine. 2014;32(48):6369-76.  https://doi.org/10.1016/j.vaccine.2014.07.012  PMID: 25442403 
  4. Palache A, Oriol-Mathieu V, Fino M, Xydia-Charmanta M, Influenza Vaccine Supply task force (IFPMA IVS). Seasonal influenza vaccine dose distribution in 195 countries (2004-2013): Little progress in estimated global vaccination coverage. Vaccine. 2015;33(42):5598-605.  https://doi.org/10.1016/j.vaccine.2015.08.082  PMID: 26368399 
  5. Li K, Yu T, Seabury SA, Dor A. Trends and disparities in the utilization of influenza vaccines among commercially insured US adults during the COVID-19 pandemic. Vaccine. 2022;40(19):2696-704.  https://doi.org/10.1016/j.vaccine.2022.03.058  PMID: 35370018 
  6. He R, Ren X, Huang K, Lei J, Niu H, Li W, et al. Influenza and pneumococcal vaccination coverage and associated factors in patients hospitalized with acute exacerbations of COPD in China: Findings from real-world data. Chin Med J (Engl). 2024;137(10):1179-89.  https://doi.org/10.1097/CM9.0000000000002790  PMID: 37488669 
  7. Wang Q, Yue N, Zheng M, Wang D, Duan C, Yu X, et al. Influenza vaccination coverage of population and the factors influencing influenza vaccination in mainland China: A meta-analysis. Vaccine. 2018;36(48):7262-9.  https://doi.org/10.1016/j.vaccine.2018.10.045  PMID: 30340886 
  8. Separovic L, Zhan Y, Kaweski SE, Sabaiduc S, Carazo S, Olsha R, et al. Interim estimates of vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2) during a delayed influenza season, Canada, 2024/25. Euro Surveill. 2025;30(4).  https://doi.org/10.2807/1560-7917.ES.2025.30.4.2500059  PMID: 39885824 
  9. Kissling E, Pozo F, Martínez-Baz I, Buda S, Vilcu AM, Domegan L, et al. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study. Influenza Other Respir Viruses. 2023;17(1):e13069.  https://doi.org/10.1111/irv.13069  PMID: 36702797 
  10. Kissling E, Maurel M, Emborg HD, Whitaker H, McMenamin J, Howard J, et al. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. Euro Surveill. 2023;28(21):2300116.  https://doi.org/10.2807/1560-7917.ES.2023.28.21.2300116  PMID: 37227299 
  11. Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, et al. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024;29(8):2400089.  https://doi.org/10.2807/1560-7917.ES.2024.29.8.2400089  PMID: 38390651 
  12. United States Centers for Disease Control and Prevention (US CDC). CDC seasonal flu vaccine effectiveness studies. Atlanta: US Department of Health and Human Services. [Accessed: 10 Jan 2025]. Available from: https://www.cdc.gov/flu-vaccines-work/php/effectiveness-studies/index.html
  13. Zhang L, Lu G, Ma C, Zhang J, Li J, Duan W, et al. Influenza vaccine effectiveness against influenza a-associated outpatient and emergency-department-attended influenza-like illness during the delayed 2022-2023 season in Beijing, China. Vaccines (Basel). 2024;12(10):1124.  https://doi.org/10.3390/vaccines12101124  PMID: 39460291 
  14. Zhang J, Zhang L, Li J, Ma J, Wang Y, Sun Y, et al. Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season. Vaccine. 2025;46:126662.  https://doi.org/10.1016/j.vaccine.2024.126662  PMID: 39731809 
  15. Chinese National Influenza Center. Influenza surveillance weekly report - 52 weeks in 2024. Beijing: CCDC. [Accessed: 10 Jan 2025]. Available from: https://ivdc.chinacdc.cn/cnic/zyzx/lgzb/202501/t20250102_303647.htm
  16. Australian Government Department of Health and Aged Care. Australian respiratory surveillance report: 17-18 November to 15 December 2024. Canberra: Australian Government Department of Health and Aged Care; 2024. Available from: https://www.health.gov.au/resources/publications/australian-respiratory-surveillance-report-17-18-november-to-15-december-2024?language=en
  17. European Centre for Disease Prevention and Control (ECDC). Communicable disease threats report–28 December 2024-3 January 2025, week 1. Solna: ECDC; 2025. Available from: https://www.ecdc.europa.eu/en/publications-data/communicable-disease-threats-report-28-december-2024-3-january-2025-week-1
  18. United States Centers for Disease Control and Prevention (US CDC). Weekly US influenza surveillance report: key updates for week 52, ending December 28, 2024. Atlanta: US Department of Health and Human Services. [Accessed: 10 Jan 2025]. Available from: https://www.cdc.gov/fluview
  19. Jones-Gray E, Robinson EJ, Kucharski AJ, Fox A, Sullivan SG. Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis. Lancet Respir Med. 2023;11(1):27-44.  https://doi.org/10.1016/S2213-2600(22)00266-1  PMID: 36152673 
  20. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017;16(7):1-14.  https://doi.org/10.1080/14760584.2017.1334554  PMID: 28562111 
  21. Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. GISAID’s Role in Pandemic Response. China CDC Wkly. 2021;3(49):1049-51.  https://doi.org/10.46234/ccdcw2021.255  PMID: 34934514 
Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Ying+Sun&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sun Ying</a>, <a href="/search?value1=Weixian+Shi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Shi Weixian</a>, <a href="/search?value1=Daitao+Zhang&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zhang Daitao</a>, <a href="/search?value1=Chunna+Ma&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ma Chunna</a>, <a href="/search?value1=Zhaomin+Feng&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Feng Zhaomin</a>, <a href="/search?value1=Jiaojiao+Zhang&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zhang Jiaojiao</a>, <a href="/search?value1=Dan+Wu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wu Dan</a>, <a href="/search?value1=Li+Zhang&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zhang Li</a>, <a href="/search?value1=Jia+Li&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Li Jia</a>, <a href="/search?value1=Wei+Duan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Duan Wei</a>, <a href="/search?value1=Yingying+Wang&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wang Yingying</a>, <a href="/search?value1=Jiaxin+Ma&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ma Jiaxin</a>, <a href="/search?value1=Lu+Zhang&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zhang Lu</a>, <a href="/search?value1=Xiaodi+Hu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hu Xiaodi</a>, <a href="/search?value1=Peng+Yang&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Yang Peng</a>, <a href="/search?value1=Quanyi+Wang&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wang Quanyi</a></span>. Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(7):pii=2500084. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500084" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500084</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 30 Jan 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 20 Feb 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.7.2500084
/content/10.2807/1560-7917.ES.2025.30.7.2500084
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error